Literature DB >> 10419913

Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression.

R Ouatu-Lascar1, R C Fitzgerald, G Triadafilopoulos.   

Abstract

BACKGROUND & AIMS: Maintenance of normal epithelial differentiation and proliferation is an important goal in cancer chemoprevention. Because acid has a dynamic effect on cell proliferation/differentiation of Barrett's esophagus (BE) ex vivo, we investigated the relationship between differentiation, proliferation, and dysplasia in BE biopsy specimens and explored the role of normalization of intraesophageal pH in altering the BE phenotype.
METHODS: Endoscopic biopsy specimens of BE (with or without dysplasia) were analyzed for (1) villin, a differentiation marker, by immunoblotting; (2) proliferating cell nuclear antigen (PCNA), a proliferation marker, by immunohistochemistry; and (3) dysplasia by histology before and after 6 months of normalization of intraesophageal pH (confirmed by 24-hour pH monitoring) with lansoprazole.
RESULTS: At baseline, there was a negative correlation (r = -0.79) between villin and PCNA expression. Six months later, PCNA expression decreased and villin expression increased (P < 0.001) in 24 patients whose intraesophageal pH normalized. Fifteen patients had persistently pathological intraesophageal acid reflux and no change in villin or PCNA expression. There were no differences in the occurrence of dysplasia after 6 months in either group.
CONCLUSIONS: In BE, there is an inverse relationship between villin and PCNA. In turn, dysplasia is unrelated to villin expression and well correlated with PCNA expression. Complete symptom eradication with lansoprazole does not guarantee normalization of intraesophageal pH profile in BE patients. Effective intraesophageal acid suppression favors differentiation and decreases proliferation. The intriguing possibility that acid suppression can be used to prevent dysplasia remains to be explored.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10419913     DOI: 10.1053/gast.1999.0029900327

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  69 in total

1.  Proton pump inhibitors for Barrett's oesophagus.

Authors:  G Triadafilopoulos
Journal:  Gut       Date:  2000-02       Impact factor: 23.059

2.  The pathogenesis of Barrett's esophagus: a process in continuum or discontinuum.

Authors:  R C Fitzgerald; M J Farthing
Journal:  Curr Gastroenterol Rep       Date:  2000-12

Review 3.  Acid suppression therapy in Barrett's esophagus: the importance of pH monitoring.

Authors:  D O Castell
Journal:  Curr Gastroenterol Rep       Date:  2000-06

4.  Oesophageal pH monitoring in Barrett's oesophagus.

Authors:  C S Neumann; B T Cooper
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

Review 5.  How should Barrett's ulceration be treated?

Authors:  J H Peters; K K Wang
Journal:  Surg Endosc       Date:  2004-01-12       Impact factor: 4.584

6.  Endoscopic therapy of Barrett's: what more do we need to know?

Authors:  J-L Van Laethem; J Devière
Journal:  Gut       Date:  2004-06       Impact factor: 23.059

Review 7.  Risk factors for neoplastic progression in Barrett's esophagus.

Authors:  Elizabeth F Wiseman; Yeng S Ang
Journal:  World J Gastroenterol       Date:  2011-08-28       Impact factor: 5.742

Review 8.  Barrett esophagus: an update.

Authors:  Rami J Badreddine; Kenneth K Wang
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-06-01       Impact factor: 46.802

9.  Acid-induced p16 hypermethylation contributes to development of esophageal adenocarcinoma via activation of NADPH oxidase NOX5-S.

Authors:  Jie Hong; Murray Resnick; Jose Behar; Li Juan Wang; Jack Wands; Ronald A DeLellis; Rhonda F Souza; Stuart J Spechler; Weibiao Cao
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-06-24       Impact factor: 4.052

Review 10.  Barrett esophagus: what a mouse model can teach us about human disease.

Authors:  Michael Quante; Julian A Abrams; Yoomi Lee; Timothy C Wang
Journal:  Cell Cycle       Date:  2012-10-24       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.